Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

References

• Rangaswami J , Bhalla V , de Boer IH , et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the american heart association. Circulation. 2020;142(17):e265–e86.
   PubMed Web of Science ®Google Scholar
• Go AS. Cardiovascular disease consequences of CKD. Semin Nephrol. 2016;36(4):293–304.
   PubMed Web of Science ®Google Scholar
• Gheith O , Farouk N , Nampoory N , et al. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49–56.
   PubMedGoogle Scholar
• Wheeler DC , James J , Patel D , et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes. Diabetes Ther. 2020;11(12):2757–2774.
   PubMed Web of Science ®Google Scholar
• Assogba FG , Couchoud C , Hannedouche T , et al. Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011. Diabetologia. 2014;57(4):718–728.
   PubMed Web of Science ®Google Scholar
• Wu B , Bell K , Stanford A , et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012. BMJ Open Diabetes Res Care. 2016;4(1):e000154.
   PubMed Web of Science ®Google Scholar
• Kainz A , Hronsky M , Stel VS , et al. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. Nephrol Dial Transplant. 2015;30(Suppl 4):iv113–8.
   PubMed Web of Science ®Google Scholar
• Neumiller JJ , Hirsch IB . Management of hyperglycemia in diabetic kidney disease. Diabetes Spectr. 2015;28(3):214–219.
   PubMedGoogle Scholar
• Aggarwal HK , Jain D , Pawar S , et al. Health-related quality of life in different stages of chronic kidney disease. QJM. 2016;109(11):711–716.
   PubMed Web of Science ®Google Scholar
• Gaede J , Oellgaard J , Ibsen R , et al. A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study. Diabetologia. 2019;62(1):147–155.
   PubMed Web of Science ®Google Scholar
• Tuttle KR , Bakris GL , Bilous RW , et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes . KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–163.
   Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes . KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int Suppl. 2020;98(45):1–120.
   Google Scholar
• Fung CS , Wan EY , Chan AK , et al. Association of estimated glomerular filtration rate and urine albumin-to-creatinine ratio with incidence of cardiovascular diseases and mortality in Chinese patients with type 2 diabetes mellitus - a population-based retrospective cohort study. BMC Nephrol. 2017;18(1):47.
   PubMed Web of Science ®Google Scholar
• Levey AS , Becker C , Inker LA . Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313(8):837–846.
   PubMed Web of Science ®Google Scholar
• Christofides EA , Desai N . Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: addressing the barriers to albuminuria testing. J Prim Care Community Health. 2021;12:21501327211003683.
   Web of Science ®Google Scholar
• Chu CD , McCulloch CE , Banerjee T , et al. CKD awareness among us adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174–183.
   PubMed Web of Science ®Google Scholar
• Stehouwer CD , Smulders YM . Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106–2111.
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Disease Prognosis C , Matsushita K , van der Velde M , Astor BC , et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• Lamprea-Montealegre JA , Shlipak MG , Estrella MM . Chronic kidney disease detection, staging and treatment in cardiovascular disease prevention. Heart. 2021;107(16):1282–1288.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association . Standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S1–S232.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation . KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60(5):850–886.
   PubMed Web of Science ®Google Scholar
• Levey AS , Stevens LA , Schmid CH , et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
   PubMed Web of Science ®Google Scholar
• Delgado C , Baweja M , Crews D , et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. J Am Soc Nephrol. 2021;32:1305–1317.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation . KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S1–S180.
   PubMed Web of Science ®Google Scholar
• Szczech LA , Stewart RC , Su HL , et al. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS One. 2014;9(11):e110535.
   PubMed Web of Science ®Google Scholar
• Tuttle KR , Alicic RZ , Duru OK , et al. Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD registry. JAMA Network Open. 2019;2(12):e1918169.
   PubMed Web of Science ®Google Scholar
• Sasso FC , Pafundi PC , Simeon V , et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetol. 2021;20(1):145.
   PubMed Web of Science ®Google Scholar
• Yamada S . First, do no harm: critical appraisal of protein restriction for diabetic kidney disease. Diabetology. 2021;2:51–64.
   Web of Science ®Google Scholar
• Marin-Penalver JJ , Martin-Timon I , Sevillano-Collantes C , et al. Update on the treatment of type 2 diabetes mellitus. World J Diabetes. 2016;7(17):354–395.
   PubMed Web of Science ®Google Scholar
• Galindo RJ , Beck RW , Scioscia MF , et al. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;41(5):756–774.
   PubMed Web of Science ®Google Scholar
• Wang F , Wang D , Lyu XL , et al. Continuous glucose monitoring in diabetes patients with chronic kidney disease on dialysis: a meta-analysis. Minerva Endocrinol. 2020. DOI:10.23736/S0391-1977.20.03284-8
   Google Scholar
• Marfella R , Sasso FC , Cacciapuoti F , et al. Tight glycemic control may increase regenerative potential of myocardium during acute infarction. J Clin Endocrinol Metab. 2012;97(3):933–942.
   PubMed Web of Science ®Google Scholar
• Sasso FC , Rinaldi L , Lascar N , et al. Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes. J Diabetes Res. 2018;2018:3106056.
   PubMed Web of Science ®Google Scholar
• Esmeijer K , Dekkers OM , de Fijter JW , et al. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep. 2019;9(1):16632.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ , Mach F , Smulders YM , et al. ESC guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2021. DOI:10.1093/eurjpc/zwab154.
   Web of Science ®Google Scholar
• Hahr AJ , Molitch ME . Management of diabetes mellitus in patients with chronic kidney disease. Clin Diabetes Endocrinol. 2015;1:2.
   PubMedGoogle Scholar
• Lozano-Maneiro L , Puente-Garcia A . Renin-angiotensin-aldosterone system blockade in diabetic nephropathy. Present evidences. J Clin Med. 2015;4(11):1908–1937.
   PubMed Web of Science ®Google Scholar
• Lewis EJ , Hunsicker LG , Bain RP , et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med. 1993;329(20):1456–1462.
   PubMed Web of Science ®Google Scholar
• Lewis EJ , Hunsicker LG , Clarke WR , et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
   PubMed Web of Science ®Google Scholar
• Brenner BM , Cooper ME , de Zeeuw D , et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869.
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes . KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2021;99(35):1–92.
   Google Scholar
• Vassalotti JA , Centor R , Turner BJ , et al. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153–62e7.
   PubMed Web of Science ®Google Scholar
• Schjoedt KJ , Andersen S , Rossing P , et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia. 2004;47(11):1936–1939.
   PubMed Web of Science ®Google Scholar
• Sato A , Hayashi K , Naruse M , et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41(1):64–68.
   PubMed Web of Science ®Google Scholar
• Bays H . Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther. 2013;4(2):195–220.
   PubMed Web of Science ®Google Scholar
• Neal B , Perkovic V , Mahaffey KW , et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Perkovic V , Jardine MJ , Neal B , et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Wiviott SD , Raz I , Bonaca MP , et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Zinman B , Wanner C , Lachin JM , et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL , Karasik A , Thuresson M , et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27–35.
   PubMed Web of Science ®Google Scholar
• Heerspink HJL , Stefansson BV , Correa-Rotter R , et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
   PubMed Web of Science ®Google Scholar
• Fioretto P , Zambon A , Rossato M , et al. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(Suppl 2):S165–71.
   PubMed Web of Science ®Google Scholar
• Yaribeygi H , Simental-Mendía LE , Banach M . The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: an update. Biomed Pharmacother. 2019;120:109526.
   Web of Science ®Google Scholar
• Zoungas S , de Boer IH . SGLT2 Inhibitors in Diabetic Kidney Disease. Clin J Am Soc Nephrol. 2021;16(4):631–633.
   PubMed Web of Science ®Google Scholar
• Tran KL , Park YI , Pandya S , et al. Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes. Am Health Drug Benefits. 2017;10(4):178–188.
   PubMed Web of Science ®Google Scholar
• Mann JFE , Orsted DD , Brown-Frandsen K , et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–848.
   PubMed Web of Science ®Google Scholar
• Tuttle KR , Lakshmanan MC , Rayner B , et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–617.
   PubMed Web of Science ®Google Scholar
• Gerstein HC , Colhoun HM , Dagenais GR , et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138.
   PubMed Web of Science ®Google Scholar
• Michos ED , Tuttle KRGLP-1 . Receptor agonists in diabetic kidney disease. Clin J Am Soc Nephrol. 2021;16:1578–1580.
   PubMed Web of Science ®Google Scholar
• Georgianos PIA R . Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney International Reports 2021; In press.
   Google Scholar
• Currie G , Taylor AH , Fujita T , et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol. 2016;17(1):127.
   PubMed Web of Science ®Google Scholar
• Haynes BA , Mookadam F , Currie G . Male gynecomastia. Mayo Clin Proc. 2009;84(8):672.
   PubMed Web of Science ®Google Scholar
• Kolkhof P , Delbeck M , Kretschmer A , et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69–78.
   PubMed Web of Science ®Google Scholar
• Barrera-Chimal J , Estrela GR , Lechner SM , et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 2018;93(6):1344–1355.
   PubMed Web of Science ®Google Scholar
• Bakris GL , Agarwal R , Chan JC , et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884–894.
   PubMed Web of Science ®Google Scholar
• Pitt B , Kober L , Ponikowski P , et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–2463.
   PubMed Web of Science ®Google Scholar
• Agarwal R , Kolkhof P , Bakris G , et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–161.
   PubMed Web of Science ®Google Scholar
• Sridhar VS , Liu H , Cherney DZI . Finerenone-A new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease. Am J Kidney Dis. 2021;78(2):309–311.
   PubMed Web of Science ®Google Scholar
• Bakris GL , Agarwal R , Anker SD , et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–2229.
   PubMed Web of Science ®Google Scholar
• Pitt B , Filippatos G , Agarwal R , et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021. DOI:10.1056/NEJMoa2110956.
   Web of Science ®Google Scholar
• Ito S , Shikata K , Nangaku M , et al. Efficacy and safety of esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, Phase II trial. Clin J Am Soc Nephrol. 2019;14(8):1161–1172.
   PubMed Web of Science ®Google Scholar
• Smart NA , Dieberg G , Ladhani M , et al. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev. 2014;6:CD007333. DOI:10.1002/14651858.CD007333.pub2
   PubMed Web of Science ®Google Scholar
• Jan MY , Wish JB . Balancing nephrology referrals with nephrologist capacity to decrease emergency dialysis starts. Kidney Int Rep. 2021;6(1):7–10.
   PubMed Web of Science ®Google Scholar
• Samal L , Wright A , Waikar SS , et al. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis. BMC Nephrol. 2015;16:162.
   PubMed Web of Science ®Google Scholar
• Oliva-Damaso N , Oliva-Damaso E , Rodriguez-Perez JC , et al. Improved nephrology referral of chronic kidney disease patients: potential role of smartphone apps. Clin Kidney J. 2019;12(6):767–770.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP , Isaman D , Petruski-Ivleva N , et al. Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. Clin Kidney J. 2021;14(6):1657–1664.
   PubMed Web of Science ®Google Scholar
• Alicic RZ , Rooney MT , Tuttle KR . Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–2045.
   PubMed Web of Science ®Google Scholar
• Musuuza J , Sutherland BL , Kurter S , et al. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. J Vasc Surg. 2020;71(4):1433–46e3.
   PubMed Web of Science ®Google Scholar
• Bongaerts BW , Mussig K , Wens J , et al. Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. BMJ Open. 2017;7(3):e013076.
   PubMed Web of Science ®Google Scholar
• Holland R , Battersby J , Harvey I , et al. Systematic review of multidisciplinary interventions in heart failure. Heart. 2005;91(7):899–906.
   PubMed Web of Science ®Google Scholar
• Jain K , Mottl AK . Comprehensive care for people with diabetic kidney disease. Diabetes Spectr. 2015;28(3):187–192.
   PubMedGoogle Scholar
• Neumiller JJ , Shubrook JH , Manley T , et al. Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: an opportunity for pharmacists. Am J Health Syst Pharm. 2021. DOI:10.1093/ajhp/zxab271
   Web of Science ®Google Scholar
• Narva AS , Norton JM , Boulware LE . Educating patients about CKD: the path to self-management and patient-centered care. Clin J Am Soc Nephrol. 2016;11(4):694–703.
   PubMed Web of Science ®Google Scholar
• Berkowitz SA , Eisenstat SA , Barnard LS , et al. Multidisciplinary coordinated care for type 2 diabetes: a qualitative analysis of patient perspectives. Primary Care Diabetes. 2018;12(3):218–223.
   PubMed Web of Science ®Google Scholar
• Maneze D , Dennis S , Chen HY , et al. Multidisciplinary care: experience of patients with complex needs. Aust J Prim Health. 2014;20(1):20–26.
   PubMed Web of Science ®Google Scholar